<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914143</url>
  </required_header>
  <id_info>
    <org_study_id>2020-261</org_study_id>
    <nct_id>NCT04914143</nct_id>
  </id_info>
  <brief_title>the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy</brief_title>
  <official_title>A Prospective, Single Center, Randomized, Double-blind Clinical Study to Evaluate the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to explore the effect of broken Ganoderma lucidum spore powder&#xD;
      on improving the quality of life and immune recovery of patients after chemotherapy.&#xD;
      Objective To observe the adjuvant treatment with broken wall Ganoderma lucidum spore powder&#xD;
      in patients with diffuse large B-cell lymphoma after standard chemotherapy according to NCCN&#xD;
      guidelines. To evaluate and compare the immunoglobulin (IGA, IgM, IgG), T cell subsets (CD3&#xD;
      +, CD4 +, CD8 +, CD4 + / CD8 +), Th1 / Th2 cytokine determination, quality of life score,&#xD;
      leukocyte recovery rate, infection rate, infection rate To evaluate the effect of Ganoderma&#xD;
      lucidum spore powder in improving the quality of life and immune function of patients after&#xD;
      chemotherapy. At the same time, the liver and kidney function and adverse drug events were&#xD;
      closely monitored during the study to explore the clinical safety of wall broken Ganoderma&#xD;
      lucidum spore powder as adjuvant drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of immunoglobulin (IGA, IgM, IgG)</measure>
    <time_frame>half a year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell subsets</measure>
    <time_frame>half a year</time_frame>
    <description>T cell subsets (CD3 +, CD4 +, CD8 +, CD4 + / CD8 +)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Th1 / Th2 cytokines</measure>
    <time_frame>half a year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo comparator group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>broken Ganoderma lucidum spore powder</intervention_name>
    <description>The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>the control group was treated with placebo after chemotherapy</description>
    <arm_group_label>placebo comparator group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diffuse large B-cell lymphoma，NOS&#xD;
&#xD;
          -  all patients were diagnosed for the first time&#xD;
&#xD;
          -  between 18-75 years old, male and female&#xD;
&#xD;
          -  ECoG 0-3 ，the expected survival was more than 6 months&#xD;
&#xD;
          -  the pregnancy test of women of childbearing age was negative; Male and female patients&#xD;
             should agree to take effective contraceptive measures during the treatment period and&#xD;
             one year of follow-up;&#xD;
&#xD;
          -  sign the informed consent before the test screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  those who are known to be allergic to the study drug or its related components; Or&#xD;
             allergic patients&#xD;
&#xD;
          -  uncontrolled psychosis&#xD;
&#xD;
          -  participating in other trials at the same time, and using experimental drugs that may&#xD;
             affect the efficacy and safety evaluation&#xD;
&#xD;
          -  impairment of liver and kidney function&#xD;
&#xD;
          -  HIV antibody positive;&#xD;
&#xD;
          -  HBsAg positive hepatitis B carriers and confirmed hepatitis B and C patients;&#xD;
&#xD;
          -  pregnant or lactating women and patients who do not agree to take effective&#xD;
             contraceptive measures;&#xD;
&#xD;
          -  the patient is unable to swallow the capsule or has a disease or condition that&#xD;
             seriously affects the gastrointestinal function;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yun liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>2ndAffiliated Hospital, School of Medicine, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xian li</last_name>
    <phone>+8615158872648</phone>
    <email>lixian2018@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yun liang</last_name>
    <phone>+8613957136178</phone>
    <email>liangyun@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2ndAffiliated Hospital, School of Medicine, Zhejiang University, China</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yun liang</last_name>
      <phone>+8613957136178</phone>
      <email>liangyun@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>broken Ganoderma lucidum spore powder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

